Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Trading 12-23 10:12:35 EST

16.74

+0.55

+3.40%

High16.92	Low15.94	Vol199.39K
Open16.14	D1 Closing16.19	Amplitude6.03%
Mkt Cap1.09B	Tradable Cap409.74M	Total Shares65.12M
T/O3.28M	T/O Rate0.81%	Tradable Shares24.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":16.74,"timestamp":1766502750081,"preClose":16.19,"halted":0,"volume":199389,"delay":0,"floatShares":24476600,"shares":65117761,"eps":0.252426,"marketStatus":"Trading","change":0.55,"latestTime":"12-23 10:12:35 EST","open":16.14,"high":16.9156,"low":15.94,"amount":3277324.2932039998,"amplitude":0.060259,"askPrice":16.78,"askSize":100,"bidPrice":16.73,"bidSize":46,"shortable":3,"etf":0,"ttmEps":0.252426,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766523600000},"marketStatusCode":2,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":16.19,"preHourTrading":{"tag":"盘前","latestPrice":15.95,"preClose":16.19,"latestTime":"08:56 EST","volume":273,"amount":4442.500062,"timestamp":1766498178915},"postHourTrading":{"tag":"盘后","latestPrice":15.88,"preClose":16.19,"latestTime":"19:36 EST","volume":24473,"amount":395840.57,"timestamp":1766450189376},"volumeRatio":0.757796,"impliedVol":1.1757,"impliedVolPercentile":0.368},"requestUrl":"/m/hq/s/GLUE/wiki","defaultTab":"wiki","newsList":[{"id":"2592630931","title":"Assessing Monte Rosa Therapeutics (GLUE) Valuation After Encouraging Phase 1/2 Prostate Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2592630931","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592630931?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:25","pubTimestamp":1766136338,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) just gave investors a fresh catalyst, sharing interim Phase 1/2 data showing 100% disease control and PSA responses in a key prostate cancer subgroup, along with plans for a follow up Phase 2 trial.\nSee our latest analysis for Monte Rosa Therapeutics.\nThat strength in the clinic has gone hand in hand with shifting sentiment in the stock, with a 150.08% 3 month share price return and 128.43% 1 year total shareholder return signaling powerful, still building...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/assessing-monte-rosa-therapeutics-glue-valuation-after-encou","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/assessing-monte-rosa-therapeutics-glue-valuation-after-encou","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GLUE","BK4539","BK4139","DCF"],"gpt_icon":0},{"id":"2592217934","title":"Why Is Monte Rosa Stock Trading Higher Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592217934","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592217934?lang=en_us&edition=fundamental","pubTime":"2025-12-17 03:37","pubTimestamp":1765913820,"startTime":"0","endTime":"0","summary":"Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/16/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/16/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/25/12/49432451/why-is-monte-rosa-stock-trading-higher-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/12/49432451/why-is-monte-rosa-stock-trading-higher-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0321505439.SGD","LU0985481810.HKD","SG9999002224.SGD","BK4599","IE00BBT3K403.USD","LU1894683264.USD","IE00B19Z3B42.SGD","BK4139","LU0058720904.USD","LU0306806265.USD","BK4225","SG9999003800.SGD","LU1066053197.SGD","IE0002270589.USD","BK4585","IE00BLSP4239.USD","LU0234572021.USD","LU1894683348.USD","LU0225284248.USD","LU0122379950.USD","BK4581","IE00B19Z3581.USD","BK4007","LU0306807586.USD","IE00BLSP4452.SGD","SG9999001176.USD","BK4592","SG9999001176.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0170899867.USD","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4195","BK4588","SGXZ57979304.SGD","BK4211","BK4534","BK4539","BK4550","GLUE","LU0456855351.SGD","LU0225771236.USD","BK4568","LU0868494617.USD","BK4203","LU1057294990.SGD","SG9999013999.USD","LU1066051498.USD","SG9999002232.USD","BK4533"],"gpt_icon":0},{"id":"2592606931","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2592606931","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592606931?lang=en_us&edition=fundamental","pubTime":"2025-12-17 02:10","pubTimestamp":1765908646,"startTime":"0","endTime":"0","summary":"Cementos Pacasmayo  said Tuesday that a Swiss company, Holcim, has signed an agreement to acquire Inversiones Aspi from the Hochschild Group, which controls 50.01% in Cementos.Shares of Cementos surged 47% as intraday trading volume advanced to nearly 3.01 million from a daily average of over 17,000.B. Riley Financial  shares soared 37% amid heavy trading after the company reported overnight a swing to Q2 earnings amid a year-over-year increase in revenue.Intraday trading volume climbed to more than 9.88 million shares from a daily average of around 699,000.Monte Rosa Therapeutics  said Tuesday that interim data from its ongoing phase 1/2 study of its investigational drug MRT-2359 combined with enzalutamide showed a 64% overall disease control rate in certain patients with metastatic castration-resistant prostate cancer.Wedbush lifted Monte Rosa's price target to $26 from $19 while maintaining the shares' outperform ratingShares of Monte Rosa jumped 9.8%, with intraday trading volume a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4127","BK4139","IE00B19Z4B17.USD","BK4539","IE0031619046.USD","IE00B7SZL793.SGD","CPAC","GLUE","IE00B66KJ199.SGD","BK4011","RILY"],"gpt_icon":0},{"id":"2592493509","title":"Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592493509","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592493509?lang=en_us&edition=fundamental","pubTime":"2025-12-17 00:11","pubTimestamp":1765901510,"startTime":"0","endTime":"0","summary":"Price: 18.37, Change: +1.92, Percent Change: +11.67","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE"],"gpt_icon":0},{"id":"2591982938","title":"Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982938","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982938?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:14","pubTimestamp":1765890895,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) has an average rating of buy and mean price target of $19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE"],"gpt_icon":0},{"id":"2591606984","title":"Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Targeted Protein Degradation","url":"https://stock-news.laohu8.com/highlight/detail?id=2591606984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591606984?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:50","pubTimestamp":1765889400,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. highlighted progress in its pipeline of molecular glue degraders , with three clinical programs advancing toward Phase 2 trials anticipated in 2026. The company is targeting highly validated proteins implicated in diseases with significant unmet medical needs, leveraging its AI-driven QuEEN platform for rational design and selectivity. Recent collaborations include a partnership with Novartis to accelerate development of degraders for immune-mediated diseases, featuring an upfront payment of $120 million and potential deal value up to $5.7 billion. Another agreement with Roche focuses on cancer and neurological disease targets, with Monte Rosa leading early-stage activities. The company anticipates additional investigational new drug applications for its pipeline over the next two years. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6ZRbW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2591032989","title":"BRIEF-Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide","url":"https://stock-news.laohu8.com/highlight/detail?id=2591032989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591032989?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:09","pubTimestamp":1765886948,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with EnzalutamideDec 16 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:MONTE ROSA THERAPEUTICS ANNOUNCES","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA5NHVSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2591989483","title":"Monte Rosa Therapeutics Announces Compelling Clinical Activity of Mrt-2359 in Combination With Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients With Androgen Receptor Mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=2591989483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591989483?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:00","pubTimestamp":1765886402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA5NHVSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2591621292","title":"Monte Rosa Therapeutics Announces Updated Phase 1/2 Study Results for MRT-2359 in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2591621292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591621292?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:01","pubTimestamp":1765832471,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. announced that it will present updated interim clinical results from its ongoing Phase 1/2 study of MRT-2359, a GSPT1-directed molecular glue degrader, in heavily pretreated, metastatic castration-resistant prostate cancer  patients. The results will be presented during a live conference call and webcast scheduled for December 16, 2025, at 8:00 a.m. ET. The webcast will be accessible via the \"Events & Presentations\" section of the company's website, with an archived version available for 30 days following the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2FRszm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","BK4588","GLUE","LU0314104364.USD","SG9999014039.USD","BK4585","BK4139","LU2210149790.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4539"],"gpt_icon":0},{"id":"2582810889","title":"Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810889","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810889?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:08","pubTimestamp":1762740521,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1QvLpm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4112","BK4539","GLUE","LU2210149790.SGD"],"gpt_icon":0},{"id":"2582981805","title":"Monte Rosa Therapeutics presents preclinical data on MRT-8102","url":"https://stock-news.laohu8.com/highlight/detail?id=2582981805","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582981805?lang=en_us&edition=fundamental","pubTime":"2025-11-10 02:20","pubTimestamp":1762712420,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of MRT-8102 at the American Heart Association’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-presents-preclinical-data-on-mrt-8102-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-presents-preclinical-data-on-mrt-8102-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MRT","BK4539","GLUE","BK4230"],"gpt_icon":0},{"id":"2582486504","title":"Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2582486504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582486504?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:30","pubTimestamp":1762619400,"startTime":"0","endTime":"0","summary":"Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and at","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184076/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-AHA-Scientific-Sessions-2025-on-the-Potential-of-MRT-8102-a-NEK7-directed-Molecular-Glue-Degrader-to-Treat-Cardiovascular-and-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRT","BK4139","BK4082","CSII","BK4539","GLUE","BK4230"],"gpt_icon":0},{"id":"2581358878","title":"Monte Rosa Therapeutics Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2581358878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581358878?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:54","pubTimestamp":1762541640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 13:54 ET (18:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","IE000M9KFDE8.USD","LU0868494708.USD","LU0106831901.USD","LU1201861249.SGD","LU2236285917.USD","LU0048573561.USD","BK4139","IE00B19Z3581.USD","LU0267386448.USD","LU0289960550.SGD","LU0251131958.USD","LU0256863811.USD","LU1668664300.SGD","LU1267930573.SGD","LU1363072403.SGD","LU1074936037.SGD","LU2361044865.SGD","IE00B7SZLL34.SGD","LU2361044949.HKD","LU1791807156.HKD","LU0130517989.USD","LU0314106906.USD","LU1267930227.SGD","LU1814569148.SGD","LU0128525689.USD","BK4585","GLUE","LU2461242641.AUD","LU1267930490.SGD","BK4501","LU0787776722.HKD","BK4539","LU0130102774.USD","BK4588","LU0708994859.HKD","LU0942090050.USD","LU0149725797.USD","LU0154236417.USD","LU0211327993.USD","LU2361045086.USD","LU0320765489.SGD","BK4207","LU0742534661.SGD","LU0251142724.SGD","LU0310799852.SGD","LU0971096721.USD","LU0310800379.SGD","LU1506573853.SGD","BK4504"],"gpt_icon":0},{"id":"2581020509","title":"Monte Rosa Therapeutics Reports Strong Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020509","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020509?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:27","pubTimestamp":1762493231,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q3 earnings. Here is a breakdown of the information Monte Rosa Therapeutics, Inc. presen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/monte-rosa-therapeutics-reports-strong-revenue-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/monte-rosa-therapeutics-reports-strong-revenue-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2581014747","title":"Monte Rosa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581014747","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581014747?lang=en_us&edition=fundamental","pubTime":"2025-11-07 04:30","pubTimestamp":1762461007,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryMonte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 33 cents per share for the qu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI3KO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2581011007","title":"Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581011007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581011007?lang=en_us&edition=fundamental","pubTime":"2025-11-07 03:15","pubTimestamp":1762456526,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating on October 23. Oliver McCammon has g...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/monte-rosa-therapeutics-strategic-partnerships-and-growth-potential-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/monte-rosa-therapeutics-strategic-partnerships-and-growth-potential-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2581906090","title":"Monte Rosa Therapeutics Showcases Pipeline Advances and Strategic Partnerships in Protein Degradation Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581906090","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581906090?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:33","pubTimestamp":1762432432,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. has presented updates on its pipeline and strategic collaborations. The company highlighted progress in its wholly owned pipeline, with multiple programs approaching Phase 2 trials in 2026 and additional investigational new drug  applications anticipated over the next two years. Monte Rosa is advancing three clinical programs targeting high medical need indications, leveraging its expertise in molecular glue degraders  and AI-driven protein-protein interaction prediction. Recent collaborations include an agreement with Novartis, under which Monte Rosa received a $150 million upfront payment and is eligible for up to $2.1 billion in milestones, along with a 30% share of U.S. profits and ex-U.S. royalties. Another partnership with Roche grants Roche the right to further develop compounds targeting cancer and neurological diseases. Monte Rosa's technology platform, QuEEN, supports the discovery and rational design of novel MGDs with high selectivity and oral d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL51FSm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2581677280","title":"Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581677280","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581677280?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:24","pubTimestamp":1762431847,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent.  This is a 38.54 percent increase over sales of $9.216","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48682830/monte-rosa-therapeutics-q3-sales-12-768m-beat-5-420m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0},{"id":"2581067282","title":"Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067282","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067282?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:20","pubTimestamp":1762431618,"startTime":"0","endTime":"0","summary":"Monte Rosa Q3 net loss widens, but revenue increases on Novartis paymentOverviewMonte Rosa Q3 net loss widens to $27.1 mln, driven by increased R&D expensesCollaboration revenue for Q3 rises to $12.8 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2581062236","title":"BRIEF-Monte Rosa Therapeutics Q3 Operating Income USD -32.975 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062236","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062236?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430457,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Q3 Operating Income USD -32.975 Million\n\n\nNov 06 (Reuters) - Monte Rosa Therapeutics Q3 collaboration revenue USD 12.768 million.\n\nQ3 net income USD -27.081 million\nQ3 operating expenses USD 45.743 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXD56B45:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4539","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.0158},{"period":"1month","weight":0.1385},{"period":"3month","weight":1.5577},{"period":"6month","weight":2.3941},{"period":"1year","weight":1.3362},{"period":"ytd","weight":1.3329}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.127698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.006096},{"month":3,"riseRate":0.5,"avgChangeRate":0.054079},{"month":4,"riseRate":0.25,"avgChangeRate":-0.206735},{"month":5,"riseRate":0.25,"avgChangeRate":-0.009649},{"month":6,"riseRate":0.5,"avgChangeRate":0.041063},{"month":7,"riseRate":0.8,"avgChangeRate":0.071272},{"month":8,"riseRate":0.4,"avgChangeRate":0.098753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.6,"avgChangeRate":0.088846}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction